Adamas Pharmaceuticals (NASDAQ:ADMS) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report released on Saturday.
Other analysts have also issued research reports about the stock. Northland Securities assumed coverage on shares of Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They set an “outperform” rating for the company. ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 13th. Needham & Company LLC set a $40.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, February 25th. Finally, Piper Jaffray Companies set a $52.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $45.14.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) opened at $27.69 on Friday. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55. Adamas Pharmaceuticals has a 12 month low of $13.50 and a 12 month high of $44.00. The firm has a market cap of $712.08, a price-to-earnings ratio of -5.49 and a beta of 1.59.
Several institutional investors and hedge funds have recently made changes to their positions in ADMS. SG Americas Securities LLC acquired a new position in shares of Adamas Pharmaceuticals during the third quarter valued at $110,000. Quantbot Technologies LP acquired a new stake in Adamas Pharmaceuticals in the third quarter worth about $119,000. Sei Investments Co. lifted its holdings in Adamas Pharmaceuticals by 1,105.0% in the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock worth $185,000 after purchasing an additional 8,033 shares during the period. Granite Springs Asset Management LLC acquired a new stake in Adamas Pharmaceuticals in the fourth quarter worth about $207,000. Finally, FNY Partners Fund LP acquired a new stake in Adamas Pharmaceuticals in the third quarter worth about $231,000. 76.08% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3256525/adamas-pharmaceuticals-adms-upgraded-at-bidaskclub-2.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.